Mirum was formed in 2018, with support from RiverVest, to advance maralixibat, an ASBT inhibitor previously developed by Lumena Pharmaceuticals, a RiverVest Fund II company. Mirum went public in July 2019, and RiverVest liquidated its position in the company in 2023.

RiverVest Fund IV 

Participated in $120 million Series A in 2018

Exit

IPO in July 2019 (Nasdaq: MIRM)

Position fully liquidated in 2023